期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

侵袭性B细胞淋巴瘤临床病理学特点与利妥昔单抗疗效的关系

下载PDF
导出
作者 刘海生 高玉环 张彦茹 赵桂敏
机构地区 河北医科大学第四医院 河北省肿瘤医院血液内科
出处 《临床荟萃》 CAS 2010年第7期610-612,共3页 Clinical Focus
基金 河北省普通高校强势特色学科项目[冀教高(2005)52号] 2009年河北省医学科学研究重点课题计划(20090154)
关键词 淋巴瘤 B细胞 利妥昔单抗 药物疗法 联合
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting[J]. J Clin Oncol,1989,7(11):1630-1636.
  • 2Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007,25 (5) : 579- 586.
  • 3The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma[J]. N Engl J Med,1993,329(14) ;987-994.
  • 4Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B- cell lymphoma treated with R-CHOP[J]. Blood, 2007,109 (5) : 1857-1861.
  • 5沈杨,姚钰,李军民,陈秋生,游建华,赵慧瑾,程澍,沈志祥.R—CHOP方案治疗弥漫大B细胞淋巴瘤的预后因素分析[J].中华血液学杂志,2008,29(4):252-257. 被引量：14
  • 6张红雨,管忠震,汪波,黄慧强,夏忠军,林桐榆.弥漫大B细胞性淋巴瘤临床病理特点与利妥昔单抗疗效的关系[J].中华肿瘤杂志,2008,30(5):381-384. 被引量：6
  • 7Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab[J]. Leuk Lymphoma, 2008,49 (3) : 462-469.
  • 8Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin ' s lymphoma:results of a phase Ⅱ trial of rituximab [J]. J Clin Oncol, 1999,17(6) : 1851-1857.

二级参考文献27

  • 1管忠震,喻俪华,何友兼,宋贞荣,张力,苏义顺,徐光川,黄小薇,周中梅,刘茂珍,崔景华.用“CHOP”方案治疗非何杰金氏淋巴瘤——103例临床疗效及毒性观察[J].癌症,1989,8(2):98-100. 被引量：30
  • 2陈愉,杜洪,胡维维,韩西群,贺莉,宋兰英,朱梅刚,赵彤.非霍奇金淋巴瘤365例WHO新分类的临床病理分析[J].诊断病理学杂志,2004,11(5):304-307. 被引量：32
  • 3张彦宁,周小鸽,张淑红,王鹏,张长淮,黄受方.非霍奇金B细胞淋巴瘤369例病理形态观察 2001年世界卫生组织淋巴组织肿瘤新分类应用体会[J].中华病理学杂志,2005,34(4):193-197. 被引量：36
  • 4吴宏菊,张清媛,陈德发,关小军,张伯龙,马军.美罗华联合CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床对比研究[J].癌症,2005,24(12):1498-1502. 被引量：33
  • 5Chuang SS, Lin CN, Li CY. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer, 2000,89 : 1586-1592.
  • 6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002,346:235-242.
  • 7Rossini F, Terruzzi E, Perego D, et al. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer, 2004,100:350-355.
  • 8Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol, 1986,4:295-305.
  • 9Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. Lancet Oncol, 2006, 7:379-391.
  • 10Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs. Eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL) : resuhs of the completed RICOVER-60 trial of the German High-Grade NonHodgkin's Lymphoma Study Group (DSHNHL). Blood, 2006, 108 : 64a.

共引文献17

临床荟萃
2010年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部